What is this study about?
The purpose of this study (AscenD-LB) is to understand if neflamapimod has an effect on cognitive function (attention, memory) in those with dementia with Lewy bodies (DLB).
What is involved?
Participants of this study will be randomly assigned to either an oral dose of neflamapimod or an inactive substitute (placebo) for 16 weeks. Neither the study participant nor the researcher will know who is receiving neflamapimod, which is called a double-blind study. Study participants may require MRI, CT, DaTscan, cognitive tests, electrocardiodiagram, physical examination, and biomarker testing.
ClinicalTrials.gov information available in the link here.
What is Neflamapimod
Neflamapimod is an oral, selective small molecule inhibitor of the protein kinase p38 alpha. Extensive research has shown that p38 alpha is a key driver of synaptic dysfunction, which leads to neurodegeneration.
Who can participate?
An individual may be able to join the study if he/she meets the following criteria:
- Man or woman 55 years of age or older
- Individual or individual's legally authorized representative willing and able to provide informed consent
- Person with probable DLB
- Currently receiving cholinesterase inhibitor therapy
- Normal or corrected eyesight and auditory ability
- No history of learning difficulties
- Have reliable informant or caregiver
The AscenD-LB study will be conducted at the following locations:
|University of Kansas Medical Center||Kansas City, KS||Emily Gamelfirstname.lastname@example.org|
|University of Rochester||Rochester, NY||Nicole Guerrero||nicole_guerrero@URMC.Rochester.edu|
|University of Washington||Seattle, WA||Yeung Tutterrowemail@example.com|
|Cleveland Clinic - Las Vegas||Las Vegas, NV||Marlen Ibarrafirstname.lastname@example.org|
|Northwest Clinical Research Center||Bellevue, WA||Leslie Gillsemail@example.com|
|Ohio State University||Columbus, OH||Brooke Eigingerfirstname.lastname@example.org|
|Summit Research Network||Portland, OR||Amanda Feldmanemail@example.com|
|Massachusetts General Hospital||Charlestown, MA||Brooke Fortinfirstname.lastname@example.org|
|Oregon Health and Science University (OHSU)||Portland, OR||Audrey Andersonemail@example.com|
|John Wayne Cancer Institute
(Pacific Neuroscience Institute)
|Santa Monica, CA||Mini Gillfirstname.lastname@example.org|
|National Clinical Research, Inc.
Alzheimer's Research Center
|Richmond, VA||Kelly Gilpatrickemail@example.com|
|New York Presbyterian Hospital - Columbia University Medical Center||New York, NY||Ruth Tejedafirstname.lastname@example.org|
|Y&L Advance Health Care dba Elite Clinical Research||Miami, FL||Nuvia Herreraemail@example.com|
|University of Virginia||Charlottesville, VA||Colleen Webberfirstname.lastname@example.org|
|University of Michigan||Ann Arbor, MI||Jackie Dobsonemail@example.com|
|Jefferson University Hospitals||Philadelphia, PA||Aaron Robertsfirstname.lastname@example.org|
|Mayo Clinic||Rochester, MN||Kevin Nelsonemail@example.com|
|University of North Carolina||Chapel Hill, NC||Carlos Velezfirstname.lastname@example.org|
|Cleveland Clinic||Cleveland, OH||Christine Whitmanemail@example.com|
|University of California||San Diego, CA||Rachel Schadefirstname.lastname@example.org|
|University of Colorado||Aurora, CO||Abigail Simpsonemail@example.com|
|Inland Northwest Research||Spokane, WA||Deann Dickinsonfirstname.lastname@example.org|